October 19, 2009 (FinancialWire) — Generex Biotechnology Corp. (NASDAQ: GNBT) (www.generex.com), a leader in drug delivery for metabolic diseases through the inner lining of the mouth, at a conference in Oran, Algeria, Generex, together with Continental Pharma Laboratories, the company’s importation, marketing, distribution, and sales agent in Algeria, announced the launch of commercial sales of Generex Oral-lyn in Algeria.

The product has been approved for importation and commercial marketing and sale in Algeria, and will be marketed and sold for the treatment of patients with Type-1 or Type-2 diabetes. The size of the diabetes population in the Eastern Mediterranean and Middle East region is approximately 24,500,000.

The launch of Generex Oral-lyn took place at Royal Hotel, Oran.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.